Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioNTech SE (BNTX – Research Report) yesterday and set a price target of $127.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tazeen Ahmad’s rating is based on the strategic acquisition of CureVac by BioNTech, which is expected to enhance BioNTech’s capabilities in developing mRNA-based therapies for oncology and infectious diseases. This acquisition is seen as a significant move to strengthen BioNTech’s mRNA cancer immunotherapy platform, aligning with their broader oncology strategy. The synergies between CureVac’s platform and BioNTech’s existing pipeline are anticipated to bolster the development of BioNTech’s mRNA franchise.
Furthermore, Tazeen Ahmad highlights the importance of BioNTech’s ongoing projects, such as the BNT327, which remains a key value driver. The collaboration with Bristol Myers Squibb (BMY) is expected to unlock the full potential of this asset. The company’s focus on accelerating pipeline development while maintaining a strong balance sheet is viewed positively, supporting the Buy rating with a price objective of $127.
According to TipRanks, Ahmad is an analyst with an average return of -2.8% and a 49.08% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Incyte, Sarepta Therapeutics, and Ascendis Pharma.
In another report released today, Deutsche Bank also maintained a Buy rating on the stock with a $140.00 price target.